Skin Reactions to Immune Checkpoint Inhibitors.
The novelty of immune checkpoint inhibitors has only recently led to the characterization of cutaneous adverse events (AEs). This, along with the substantial rate of cutaneous reactions, has left many clinicians without sufficient familiarity to diagnose and treat. In the following chapter, we will review the categories of these drugs, common cutaneous effects, their grading, and management options.
Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1452, Houston, TX, 77030, USA. APatel11@mdanderson.org.
Anisha B
AB
Patel
Department of Dermatology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1452, Houston, TX, 77030, USA.
Omar
O
Pacha
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000378:metabolism; D003875:Drug Eruptions / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects* / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
Anti-CTLA4; Anti-PD1; Dermatitis; Immune checkpoint inhibitors; Immunotherapy; Ipilimumab; Nivolumab; Pruritus; Rash